Reliance Steel & Aluminum Guides Q1 Adj EPS Above View As Q4 Results Top Estimates - Quick Facts

While reporting financial results for the fourth quarter on Thursday, metals service center company Reliance Steel & Aluminum Co. (RS) said it expects adjusted earnings for the first quarter in a range of $7.05 to $7.15 per share, as the company expects its average selling price per ton sold for quarter to be up 5 to 7 percent.

On average, five analysts polled by Thomson Reuters expect the company to earn $5.09 per share for the quarter. Analysts' estimates usually exclude special items.

On Tuesday, the Board of Directors declared a 27.3 percent higher quarterly cash dividend of $0.875 per share of common stock, payable on March 25, 2022 to stockholders of record as of March 11, 2022.

For the fourth quarter, net income attributable to the company soared to $421.3 million or $6.76 per share from $129.6 million or $2.04 per share in the prior-year quarter.

Excluding items, adjusted net income attributable to the company was $6.83 per share. On average, seven analysts polled by Thomson Reuters expected the company to report earnings of $5.22 per share. Analysts' estimates typically exclude special items.

Net sales for the quarter soared 86.9 percent to $3.99 billion from $2.13 billion in the same quarter last year. Analysts expected revenue of $3.83 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT